OPKO Health's (OPK) ModeX Therapeutics subsidiary launched phase 1 clinical trials for an Epstein-Barr virus vaccine candidate in partnership with Merck (MRK).
The first participant was dosed in the MDX2201 study, which will assess safety and tolerability in up to 200 healthy adults, ModeX said Tuesday in a statement, and this stage triggers an undisclosed cash milestone payment to ModeX from Merck.
The vaccine candidate targets multiple viral proteins to stimulate immunity against EBV, which causes infectious mononucleosis and is linked to various cancers and multiple sclerosis.
OPKO shares rose 4.1% in recent Tuesday trading, and Merck gained 2.7%.
Price: 1.51, Change: +0.06, Percent Change: +4.14
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。